The purpose of the trial is to find out whether adding SIL204‑SL to standard chemotherapy improves how long patients live compared with chemotherapy alone, especially in tumors that have specific genetic changes known as KRAS G12D or KRAS G12V. These genetic changes are mutations that can make the cancer grow faster.

Participants are randomly placed into one of two groups: one group receives the new drug plus chemotherapy, the other receives chemotherapy only. Treatment is given in several cycles over a period of months, and patients return for regular check‑ups that include blood tests and imaging scans such as CT to look at the tumor. Doctors also watch for any side effects and record how patients feel during the study, with follow‑up continuing for up to two years after the first treatment.

The purpose of the study is to see whether the medicine can lower the amount of abnormal genetic material (BCR::ABL1) in the blood after one year. Participants will take the tablet each day for up to two years and will have regular visits where blood is drawn to check the genetic material using a test called PCR and a more detailed test called NGS.

During the study, quality of life will be asked about at several time points, and doctors will also watch for any signs that the disease gets worse or that the patient experiences serious side effects.

The purpose is to keep providing these medicines to people who are still benefiting after finishing a previous trial. Participants will continue to take the assigned medicine(s) for a period of time, visiting the clinic periodically for check‑ups and lab tests to see how they are doing.

Doctors will look for any ongoing benefit, such as the cancer not growing, and will also record any side effects, including changes in blood work or physical exam findings. The study does not involve any additional experimental procedures beyond the regular medication schedule.

The purpose of the study is to find out if the drug combination can lead to a clinical complete response, meaning no detectable cancer after treatment, and to see how many participants remain free of disease for two years. Researchers will also record any side effects and overall safety.

Participants will receive the two medicines together in a series of treatment cycles over several months, with regular doctor visits, scans, and lab tests to check how the cancer is responding and to monitor health. After the treatment period, follow‑up visits will continue for up to two years to observe long‑term outcomes.

The purpose of the study is to understand how safe and tolerable ATTR-01 is for patients with these types of cancers. The study will also look at how well the treatment works in shrinking or controlling the tumors. ATTR-01 is a genetically modified virus that specifically targets cancer cells that have a certain protein on their surface. Once inside the cancer cells, it helps the body’s immune system to fight the cancer by producing a cancer-fighting antibody called atezolizumab.

Participants in the study will receive either the ATTR-01 treatment or a placebo. The study will be conducted in different phases to determine the best dose of the treatment and to monitor its effects over time. Patients will be closely observed for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information that could lead to new treatment options for people with these types of cancers in the future.

Table of Contents

• What is Ammonium Chloride?
• Medical Uses
• How It Works
• Administration
• Current Clinical Trials
• Potential Side Effects
• Precautions and Considerations

What is Ammonium Chloride?

Ammonium chloride is a chemical compound that has various medical applications. It’s primarily used to influence the body’s acid-base balance, particularly by increasing the acidity of blood and urine^[1][2]. In medical terms, this process is known as acidification. Understanding how ammonium chloride works can help patients better comprehend its use in different medical conditions and research studies.

Medical Uses

Ammonium chloride is being studied and used for several medical purposes:

• Diuretic Resistance in Heart Failure: Researchers are investigating its potential in treating patients with heart failure who have become resistant to diuretics (medications that help remove excess fluid from the body)^[1].
• Pharmacokinetic Studies: It’s used to alter urine pH in studies examining how the body processes certain drugs^[2].
• Metabolic Studies: Ammonium chloride is employed in research to study how changes in blood pH affect the body’s use of proteins and amino acids^[3].

How It Works

Ammonium chloride works by influencing the body’s acid-base balance:

• Increasing Acidity: When taken orally, it can lower the pH of blood and urine, making them more acidic^[2].
• Affecting Kidney Function: It may alter how the kidneys handle sodium and other electrolytes, which is particularly relevant in heart failure research^[1].
• Metabolic Effects: Changes in blood pH can affect how the body uses proteins and amino acids, which is why it’s used in nutritional studies^[3].

Administration

Ammonium chloride is typically administered orally, but the dosage and frequency can vary depending on the specific medical use or study:

• In Diuretic Resistance Studies: Patients may receive 75 mmol twice daily for two days, followed by a single 150 mmol dose on the third day^[1].
• In Pharmacokinetic Studies: A dosage of 1 g every 3 hours for 33 hours (totaling 12 doses) has been used^[2].
• In Metabolic Studies: The dosage is adjusted to achieve a specific target blood pH range^[3].

Current Clinical Trials

Several ongoing clinical trials are exploring the potential benefits of ammonium chloride:

• Diuretic Resistance in Heart Failure: A study is investigating how ammonium chloride affects sodium reabsorption in the kidneys of heart failure patients^[1].
• Drug Metabolism: Researchers are examining how changes in urine pH, induced by ammonium chloride, affect the body’s processing of certain medications^[2].
• Nutritional Status in Kidney Disease: A study is looking at how blood pH changes, caused by ammonium chloride, impact protein utilization in patients with end-stage renal disease^[3].

Potential Side Effects

While the clinical trials don’t explicitly list side effects, it’s important to note that altering the body’s acid-base balance can have various effects:

• Gastrointestinal Discomfort: Nausea or stomach upset may occur.
• Electrolyte Imbalances: Changes in blood chemistry could potentially affect electrolyte levels.
• Metabolic Changes: Alterations in how the body processes proteins and amino acids may occur^[3].

Precautions and Considerations

Patients should be aware of the following:

• Medical Supervision: Ammonium chloride should only be used under strict medical supervision, especially given its effects on blood pH^[1][2][3].
• Monitoring: Regular blood tests may be necessary to monitor pH levels and electrolyte balance.
• Interactions: It may interact with other medications, particularly those affecting kidney function or acid-base balance.
• Not for Self-Medication: Ammonium chloride is primarily used in research settings and should not be used for self-medication.

Two treatment approaches are being compared. One group receives a combination of three drugs after an initial chemotherapy period: a taxane called paclitaxel, an antibody that blocks blood‑vessel growth named ramucirumab, and an immune‑system‑activating antibody called tislelizumab. The other group continues the standard chemotherapy regimen together with tislelizumab. Paclitaxel works by stopping cancer cells from dividing, ramucirumab stops new blood vessels that feed the tumor, and tislelizumab helps the body’s immune cells recognize and attack cancer.

The purpose of the trial is to determine whether the switch to the three‑drug combination can keep the disease from getting worse for a longer time compared with continuing the original chemotherapy. After about three months of initial therapy, participants are randomly assigned to one of the two arms and receive treatment cycles every few weeks. Tumor scans are performed roughly every two months to check for growth, and the time from random assignment until the cancer progresses or the patient dies is recorded as PFS. Safety checks and quality‑of‑life questionnaires are also completed throughout the study.

Participants are randomly assigned to receive either the combination therapy or a single oral drug, and treatment continues until disease progression or unacceptable side effects occur. Visits include regular health checks, blood tests, and imaging scans to monitor the tumor and overall health. The study follows patients for several months to record how long they live, how long the disease stays stable, and any side effects that arise.

Participants receive three cycles of the infusion, each given several weeks apart, and then are monitored for signs that the disease returns or worsens. Follow‑up includes regular scans and doctor visits to check for any new growths, side effects, or overall health changes. The study records the time until any cancer recurrence, any death related to the disease, and any serious side effects, using standard criteria such as RECIST 1.1 to measure tumor changes.

After the surgery, each person receives the assigned injection—either under the skin (subcutaneous) or into a muscle (intramuscular)—on a schedule set by the study team. Follow‑up visits are planned regularly to check health, monitor any side effects, and assess overall well‑being.

During the study, doctors will watch for any adverse events (unwanted health problems) and ask participants to complete questionnaires about their quality of life and daily functioning. This information helps determine if the treatment is safe and if it improves outcomes compared with the control injection.

Participants receive the drug in a stepwise manner, starting with low doses that are gradually increased to find a level that can be tolerated without serious side effects. Once a safe dose is identified, additional participants receive that dose to see whether the cancer shows signs of shrinking or slowing. Throughout the study, regular visits include physical examinations, blood tests that measure substances such as PSA (a protein that can indicate prostate cancer activity), and imaging scans that create pictures of the inside of the body. Any side effects, changes in laboratory results, or new symptoms are recorded, and the drug may be stopped if safety concerns arise.

The main aim of the study is to see whether this new regimen works better and is safe compared with the usual care for these cancers.

Participants will receive the study medicines in repeated treatment cycles, each lasting a few weeks, with regular check‑ups to monitor tumor size and overall health. Tumor changes are measured using standard imaging and a set of rules called RECIST 1.1. The study looks at how long patients live without the cancer getting worse, known as PFS, and how long patients live overall, referred to as OS. Blood tests and heart checks are done throughout to watch for side effects.